On December 16, 2016, Genentech filed preliminary responses in IPR2016-01693 and IPR2016-01694. Mylan filed both IPR petitions in August against patent 6,407,213, which covers humanized antibody polypeptides and methods for their preparation and use. The patent does not focus on any particular therapy, but Genentech notes that the approach was used to develop Herceptin®, Perjeta®, Avastin®, Lucentis®, and Xolair®.
To keep current on these and other IPRs related to biosimilars, check out our frequently updated IPR Tracker.
